Cash Flow Statement

Currency: NOK

	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023	Mar-2024	Jun-2024	Sep-2024	Dec-2024	Mar-2025	Jun-2025
Operating Cash Flow
Net Income	(48)	(63)	(36)	(43)	(56)	(60)	(106)	(99)	(88)	(86)	(76)	(81)	(94)	(89)	(73)
Depreciation & Amortization	0	0	0	0	1	0	0	0	0	1	1	2	1	1	1
Other Non-Cash Items	4	3	2	2	1	2	3	4	4	3	3	2	1	1	0
Cash Taxes Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Interest Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change in Working Capital	(1)	4	157	4	1	4	8	0	(13)	(20)	(15)	(4)	22	28	8
Cash from Operating Activities	(45) N/A	(56) -24%	123 N/A	(38) N/A	(53) -40%	(54) -3%	(95) -75%	(95) +0%	(97) -2%	(102) -5%	(87) +15%	(82) +6%	(70) +14%	(59) +16%	(64) -8%
Investing Cash Flow
Capital Expenditures	0	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	0	0	0	0	0
Other Items	0	0	0	(50)	(49)	(51)	(41)	19	30	40	44	34	25	15	(59)
Cash from Investing Activities	0 N/A	(0) N/A	(0) -191%	(50) -48 981%	(49) +1%	(51) -4%	(41) +21%	19 N/A	30 +55%	40 +36%	44 +9%	34 -23%	25 -27%	15 -39%	(59) N/A
Financing Cash Flow
Net Issuance of Common Stock	214	214	0	0	0	0	0	0	0	0	50	50	161	161	0
Net Issuance of Debt	0	0	0	0	(1)	0	0	0	(1)	(1)	(1)	(2)	(1)	(1)	(1)
Other	0	0	0	0	(0)	0	0	0	(0)	(0)	(3)	(3)	(11)	(11)	(8)
Cash from Financing Activities	214 N/A	214 +0%	0 N/A	0 N/A	(1) N/A	0 N/A	0 N/A	0 N/A	(0) N/A	(1) -39 400%	45 N/A	45 N/A	149 +231%	149 +0%	103 -31%
Change in Cash
Net Change in Cash	169 N/A	158 -6%	123 -22%	(88) N/A	(103) -17%	(106) -3%	(135) -28%	(76) +44%	(67) +11%	(62) +7%	2 N/A	(3) N/A	103 N/A	105 +2%	(20) N/A
Free Cash Flow
Free Cash Flow	(45) N/A	(56) -24%	123 N/A	(38) N/A	(53) -40%	(54) -3%	(95) -75%	(95) +0%	(97) -2%	(102) -5%	(87) +15%	(82) +6%	(70) +14%	(59) +16%	(64) -8%

Lytix Biopharma AS
F:6BG